1. Effects of imatinib on the expression of SHIP gene and apoptosis of K562 cells
Tumor 2007;27(11):853-856
Objective: To observe the changes of SHIP, caspase-1, caspase-3, caspase-9 and bcl-2 gene expression levels in K562 cells after mesylate imatinib (MI) treatment and explore the possible mechanism for apoptosis-inducing effects of imatinib. Methods: K562 cells were cultured with MI at different concentrations. The cells were collected at different time points. Real-time quantitative PCR was used to detect the expression level of SHIP gene. Semi-quantitative reverse transcriptase PCR was used to detect the mRNA transcription of anti-apoptotic gene bcl-2 and pro-apoptotic genes caspase-1, caspase-3 and caspase-9. The cell proliferation was measured by MTT assay. The cell apoptosis was analyzed by Annexin V/PI double staining flow cytometry. Results: MI significantly increased the expression of SHIP gene in a time-and dose-dependent manner. Caspase-9 gene was also up-regulated after MI treatment and had linear correlation with SHIP gene expression. The expression levels of caspase-1, caspase-3 and bcl-2 had no significant changes. MI down-regulated the proliferation and induced the apoptosis of K562 cells. The morphological changes of typical of apoptosis were observed. Conclusion: MI significantly increases the expressions of SHIP gene and caspase-9 gene and induces apoptosis of K562 cells. The mechanism for the apoptosis-inducing effects of imatinib may be associated with the up-regulation of SHIP and caspase-9 gene.
2.The effects of transcranial magnetic stimulation on motor function in patients with Parkinson's disease: A meta-analysis
Hai YUAN ; Lu JIN ; Xiaotong WANG ; Huiming REN ; Ying CHENG
Chinese Journal of Physical Medicine and Rehabilitation 2010;32(12):932-934
Objective To explore the effects of transcranial magnetic stimulation (TMS) on motor function in patients with Parkinson's disease (PD) using meta-analysis. Methods Eight comparative studies of the effects of TMS were meta-analyzed. Results The combined studies confirmed a significant difference before and after TMS treatment. Between the experimental and control groups the effect was also highly significant. Conclusion TMS may play an active role in the rehabilitation of motor function for patients with Parkinson's disease.
4.Preparation and stability of β-carotene loaded using mesoporous silica nanoparticles as carriers system.
Jing LIU ; Zhi-hui REN ; Hai-yuan WANG ; Xing-hua JIN
China Journal of Chinese Materia Medica 2015;40(18):3579-3584
1,3,5-Trimethylbenzene (1,3,5-TMB) was used as the pore-enlarging modifier to expand the pore size of MCM-41 (mobil company of matter) mesoporous silica nanoparticles. The solvent impregnation method was adopted to assemble non-water-soluble β-carotene into the pore channel of MCM-41. The MCM-41 and drug assemblies were characterized by TEM, FT-IR, elemental analysis and N2 adsorption-desorption. The results showed that MCM-41 has good sphericity and regular pore structure. The research also investigated the optimal loading time, the drug loading and the vitro stability of the β-carotene. As a drug carrier, the modified MCM-41 showing a shorter drug loading time, the drug loading as high as 85.58% and the stability of β-carotene in drug assemblies has improved. The study of this new formulation provides a new way for β-carotene application.
Drug Carriers
;
chemistry
;
Drug Delivery Systems
;
Drug Stability
;
Nanoparticles
;
chemistry
;
Silicon Dioxide
;
chemistry
;
beta Carotene
;
chemistry
;
pharmacology
6.Inhibitory effect of an small peptide that interferes with Fc?-receptor recognition on antineutrophil cytoplasmic antibodies induced activity of neutrophils
Xiang-Ling WANG ; Nan CHEN ; Hai-Jin YU ; Hong REN ; Wei-Ming WANG ; Li-Yan NI ;
Chinese Journal of Rheumatology 2001;0(05):-
Objective Despite regular treatment,antineutrophil eytoplasmie antibodies(ANCA)asso- ciated systemic vasculitis(AASV),in which the role of Fc?Rs has been established,are still associated with significant long-term mortality and remain an important cause of end-stage renal failure.ANCA plays an im- portant role in the pathogenisis of primary systemic small vessel vasculitis(PSV)by their potential to activate neutrophils.Because the interaction between ANCA and its receptors on the Fc portion of immunoglobulins (Fc?R)on neutrophils is essential in the activation process,we investigate the inhibitory,effect of tg19320 on ANCA induced activation of neutrophils,which is a tetrameric tripeptide that interferes with IgG/Fe?Rs in- teraction.Methods We prepared tg19320 by solid-phase peptide syntbesis.The binding between tg19320 and human IgG was assessed by enzyme-linked immunosorbent assay.The biological activity of tg19320 to intefere with FcF?receptor recognition was identified by rosette formation assay.ANCA IgG was prepared from the sera of active Wegener's granulomatosis(WG)and microscopic polyangiitis(MPA)patients.Neu- trophils isolated from the blood of healthy volunteers were primed with TNF-?(2 ng/ml)and then incubated with ANCA IgG(200?g/ml),or pretreated with tg19320(2.5 mg/ml)and then added with ANCA IgG.Su- peroxide burst of neutrophils was determined by Ferri-cytochrome reduction assay.Results We found that tg19320 bound tightly to human IgG in a dose dependent manner and the inhibition of the rosette formation between SRBC-IgG and U937 cells was statistically significant(20.3% vs 53.2%,P
7.Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Shu-Kai QIAO ; Xiao-Nan GUO ; Jin-Hai REN ; Han-Yun REN
Chinese Medical Journal 2015;128(9):1215-1222
BACKGROUNDLenalidomide has emerged as an important treatment for patients with multiple myeloma (MM). However, its role in the management of MM is still controversial and requires further clarification. The aim of this study was to evaluate efficacy and safety of lenalidomide for MM using a meta-analysis.
METHODSWe searched the electronic databases including: PubMed, EMBASE and the Cochrane Center Register of Controlled Trials. Seven randomized clinical trials were identified, which included a total of 2357 patients with MM who received lenalidomide-containing, noncontaining lenalidomide regimens or placebo as induction therapy or maintenance therapy. The outcomes included overall response (OR) rate, complete response (CR) rate, 3-year progression-free survival (PFS) rate, 3-year overall survival (OS) rate, and different types of treatment-related adverse events. We calculated the risk ratios (RRs) as well as their 95% confidence intervals of these outcomes and pooled the results using RevMan 5.2 software.
RESULTSFor patients with previously untreated MM, OR rate and CR rate was significantly higher in lenalidomide-containing group than the control group. For relapsed or refractory MM patients, lenalidomide-containing regimens significantly improved the OR rate, CR rate, 3-year PFS rate and 3-year OS rate. With regard to MM patients after autologous stem cell transplantation, lenalidomide maintenance therapy significantly improved 3-year PFS rate but did not result in improved 3-year OS rate. In terms of toxicities, lenalidomide therapy has a higher rate of Grade 3-4 grade cytopenias, infection, deep-vein thrombosis, and diarrhea. Furthermore, the incidence of second primary malignancies was significantly higher in the lenalidomide group.
CONCLUSIONSThe lenalidomide-containing regimens as induction therapy clearly increased response rates and improved intervals of survival with acceptable toxicity rates for patients with MM. However, when physicians choose to use the lenalidomide as maintenance therapy, whether the benefits outweigh the risks should be taken into account.
Angiogenesis Inhibitors ; adverse effects ; therapeutic use ; Humans ; Multiple Myeloma ; drug therapy ; Randomized Controlled Trials as Topic ; Thalidomide ; adverse effects ; analogs & derivatives ; therapeutic use ; Treatment Outcome
8.Effect of formula of removing both phlegm and blood stasis in improving hemorheology and blood fat of mini-swine with coronary heart disease of phlegm-stasis cementation syndrome.
Cheng-Ren LIN ; Lei LI ; Jian-Xun REN ; Min WANG ; Jun-Mei LI ; Hong-Hai LI ; Zheng-Yan GE ; Long JIN ; Ming-Jiang YAO ; Jian-Xun LIU
China Journal of Chinese Materia Medica 2014;39(2):300-303
OBJECTIVETo observe effect of formula of removing both phlegm and blood stasis (TYTZ) in improving hemorheology and blood fat of mini-swine with coronary heart disease of phlegm-stasis cementation syndrome.
METHODThirty-six Chinese mini-swine were randomly divided to six groups: the normal control group, the model group, the Shujiangzhi group and TYTZ groups with doses of 2.0, 1.0 and 0.5 g x kg(-1), with six mice in each group. Except for the normal control group, all of other groups were fed with high-fat diet for 2 weeks. Interventional balloons are adopted to injure their left anterior descending artery endothelium. After the operation, they were fed with high-fat diet for 8 weeks to prepare the coronary heart disease model of phlegm-stasis cementation syndrome. In the 8th week after the operation and administration, the changes in hemorheological parameters, serum lipid level, myocardial ischemia level and range were observed.
RESULTCompared with the normal control group, the model group showed significant increase in serum TC, TG, LDL-C and VLDL-C levels (P < 0.01), whole blood viscosity under the shear rate of 5 s (-1) and 60 s (-1) (P < 0.01), and myocardial ischemia degree and range (P < 0.01). Compared with the model group, TYTZ groups revealed significant decrease in myocardial ischemia degree and range (P < 0.01), serum TC, TG, LDL-C and VLDL-C levels (P < 0.05 or P < 0.01) and whole blood viscosity under the shear rate of 5 s(-1) and 60 s(-1) (P < 0.05).
CONCLUSIONTYTZ could improve the abnormal hemorheology in Chinese mini-swine with coronary heart disease of phlegm-stasis cementation syndrome, and regulate serum lipid, with a certain efficacy for coronary heart disease of phlegm-stasis cementation syndrome.
Animals ; Coronary Disease ; blood ; metabolism ; physiopathology ; therapy ; Female ; Hemorheology ; Lipids ; blood ; Male ; Medicine, Chinese Traditional ; methods ; Mucous Membrane ; secretion ; Swine ; Swine, Miniature
9.Bone marrow-derived mesenchymal stem cells regulate the proliferation and activity of natural killer cells.
Hai-Fei WANG ; Yong-Jin SHI ; Han-Yun REN
Journal of Experimental Hematology 2012;20(2):438-442
This study was aimed to explore the effect of bone marrow-derived mesenchymal stem cells (MSC) on proliferation and activity of natural killer (NK) and NK-T cells. MSC was co-cultured with peripheral mononuclear cells from healthy donors in presence of IL-2, phytohemagglutinin (PHA) and mouse anti-human CD3 McAb (culture condition known to expand NK cells). The ratio of NK cells and NK-T cells was measured by flow cytometry and the effect of MSC on killing activity of NK cells against K562 cells was detected by MTT method after co-cultured with different densities of MSC. The results showed that MSC inhibited the production of NK cells in a dose-dependent manner generally. At the densities of 0, 1 × 10(5) and 5 × 10(5)/ml, the ratios of NK cells in the co-culture conditions were (16.9 ± 4.6), (14.0 ± 8.6) and (6.4 ± 4.6), respectively (P < 0.05). However, MSC could promote the formation of NK cells at lower MSC density (1 × 10(4)/ml), the ratio of NK cells reached to (20.9 ± 7.1), which was higher than that of culture condition without MSC (P < 0.05). The different densities of MSC in the co-culture conditions had no much influence on the ratio of NK-T cells (P > 0.05). MTT assay showed that the killing activity of suspended cells in co-culture system against K562 cells was parallel with the ratio of NK cells. Different densities of MSC regulated bidirectionally killing activity of NK to K562 cells by regulating bidirectionally ratio of NK cells. It is concluded that the MSC can promote the formation of NK cells and enhance its activity against tumor cells in the lower doses, while suppress the formation of NK cells and attenuate its tumor-killing effect in higher dose condition.
Bone Marrow Cells
;
cytology
;
Cell Proliferation
;
Coculture Techniques
;
Humans
;
K562 Cells
;
Killer Cells, Natural
;
cytology
;
Mesenchymal Stromal Cells
;
cytology
;
Natural Killer T-Cells
;
cytology
10.Gene Gly82Ser polymorphism of receptor of advanced glycaton end products in patients with transient ischemia attack
Hai-Ping WANG ; Ren-Liang ZHAO ; Xiao-Jin SONG ; Chen ZHANG ; Ji-Jun TENG ; Yu-Qiang SONG ;
Chinese Journal of Neurology 2005;0(12):-
Objective To explore the relationship between receptor of advanced glycaton end products(RAGE)gene Gly82Ser polymorphism and patients with transient ischemia attack(TIA).Methods The Gly82Ser gene at the position of RAGE gene exon 3 was identified by a polymerase chain reaction- restriction fragment length polymorphism(PCR-RFLP)method in 70 cases of TIA & Diabetes(DM), 60 of simply TIA and 66 healthy control subjects.Results The genotypes of RAGE gene Gly82Ser identified were GG, GS and SS.The frequencies of RAGE gene Gly82Ser GS heterozygous genotype of TIA & DM and control were respectively 62.9% and 43.9%, significantly higher in TIA & DM patients than in control subjects(OR 2.036, 95% CI 1.021--4.062, P=0.042), however no significant difference was found between simply TIA and control(53.3% vs 43.9%, OR 1.299,95% CI O.644--2.618, P=0.465). Significant difference of the frequency of S allele was found neither between TIA & control and control(being 34.3% and 26.5%, respectively, OR 1.446,95% CI 0.859--2.434, P=0.164), nor between simple TIA and control(28.3% vs 26.5%, OR 1.096,95%CI 0.630--1.907, P=0.746).Conclusions RAGE gene Gly82Ser GS heterozygous genotype may be associated with TIA & DM patients.RAGE gene Gly82Ser polymorphism is a risky factor for TIA & DM patients, but not for TIA patients.